Overview

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

Status:
Completed
Trial end date:
2018-03-04
Target enrollment:
Participant gender:
Summary
Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb